Pivotal Trial of Oral HZN-825 in Treating dcSSc Enrolls 1st Patient

Pivotal Trial of Oral HZN-825 in Treating dcSSc Enrolls 1st Patient

312355

Pivotal Trial of Oral HZN-825 in Treating dcSSc Enrolls 1st Patient

A first patient has been enrolled in a pivotal Phase 2b clinical trial testing the safety and effectiveness of HZN-825, Horizon Therapeutics‘ oral investigational medicine for people with diffuse cutaneous systemic sclerosis (dcSSc), a form of systemic scleroderma. The trial (NCT04781543) aims to enroll 300 people, between the ages of 18 and 75, with dcSSc whose disease symptoms — other than Raynaud’s phenomenon — first became evident less than three years ago, among additional criteria. The trial…

You must be logged in to read/download the full post.